Trial intelligence / Profile preview

Phase IIa Study of AK106-001616 in Rheumatoid Arthritis

2008-006075-75Phase 2Completed

Sponsor
Asahi Kasei Corporation
Start
Feb 2009
Modality
Small Molecules
Countries
1
01

Overview

Phase 2, randomised, double-blind trial of AK106-001616 in rheumatoid arthritis (RA) (2 arms), sponsored by Asahi Kasei Corporation. Primary endpoint: Pharmacodynamic endpoints. Started Feb 2009; status: completed.

02

Drugs

AK106-001616
03

Conditions

rheumatoid arthritis (RA)

Beyond the preview

Go deeper on 2008-006075-75.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2008-006075-75.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call